Trials / Unknown
UnknownNCT05240859
Real World Study of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis
A Multicenter, Prospective, Observational Real World Study For the Efficacy and Safety of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,600 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this multicenter, prospective, Observational study is to assess the Efficacy and Safety of an Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis in the real world setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Geleli | Adalimumab Biosimilar |
Timeline
- Start date
- 2022-02-22
- Primary completion
- 2024-02-28
- Completion
- 2024-08-30
- First posted
- 2022-02-15
- Last updated
- 2022-02-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05240859. Inclusion in this directory is not an endorsement.